ES2429013T3 - Procedimientos e intermedios para la preparación de un inhibidor macrocíclico de la proteasa de VHC - Google Patents

Procedimientos e intermedios para la preparación de un inhibidor macrocíclico de la proteasa de VHC Download PDF

Info

Publication number
ES2429013T3
ES2429013T3 ES09801447T ES09801447T ES2429013T3 ES 2429013 T3 ES2429013 T3 ES 2429013T3 ES 09801447 T ES09801447 T ES 09801447T ES 09801447 T ES09801447 T ES 09801447T ES 2429013 T3 ES2429013 T3 ES 2429013T3
Authority
ES
Spain
Prior art keywords
formula
compound
xxa
salt
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09801447T
Other languages
English (en)
Spanish (es)
Inventor
Andras Horvath
Dominic John Ormerod
Dominique Paul Michel DEPRÉ
Véronique CERPENTIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Ortho McNeil Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Ortho McNeil Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2429013T3 publication Critical patent/ES2429013T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/475Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES09801447T 2008-12-23 2009-12-22 Procedimientos e intermedios para la preparación de un inhibidor macrocíclico de la proteasa de VHC Active ES2429013T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08172691 2008-12-23
EP08172691 2008-12-23
PCT/EP2009/067715 WO2010072742A1 (en) 2008-12-23 2009-12-22 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv

Publications (1)

Publication Number Publication Date
ES2429013T3 true ES2429013T3 (es) 2013-11-12

Family

ID=40548041

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09801447T Active ES2429013T3 (es) 2008-12-23 2009-12-22 Procedimientos e intermedios para la preparación de un inhibidor macrocíclico de la proteasa de VHC

Country Status (22)

Country Link
US (2) US8927722B2 (enExample)
EP (1) EP2382198B1 (enExample)
JP (1) JP5687631B2 (enExample)
KR (1) KR101734507B1 (enExample)
CN (1) CN102264715B (enExample)
AR (1) AR074863A1 (enExample)
AU (1) AU2009331530B2 (enExample)
BR (1) BRPI0923393B1 (enExample)
CA (1) CA2745565C (enExample)
CY (1) CY1114488T1 (enExample)
DK (1) DK2382198T3 (enExample)
ES (1) ES2429013T3 (enExample)
HR (1) HRP20130906T1 (enExample)
IL (1) IL213246A (enExample)
MX (1) MX2011006764A (enExample)
PL (1) PL2382198T3 (enExample)
PT (1) PT2382198E (enExample)
RU (1) RU2016120007A (enExample)
SI (1) SI2382198T1 (enExample)
SM (1) SMT201300116B (enExample)
TW (1) TWI461424B (enExample)
WO (1) WO2010072742A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923393B1 (pt) 2008-12-23 2018-06-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. "processos para preparar um inibidor de protease de hcv macrocíclico e intermediários e uso".
KR20140063726A (ko) * 2011-09-22 2014-05-27 얀센 파마슈티칼즈, 인코포레이티드 Hcv의 거대고리 단백질 분해효소 억제제의 제조 방법 및 중간물질
MX347650B (es) 2011-10-28 2017-05-05 Janssen Pharmaceuticals Inc Procedimiento mejorado para preparar un compuesto intermedio del inhibidor de proteasa macrociclico tmc 435.
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
PT2861604T (pt) 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
AR091279A1 (es) * 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
ES2656087T3 (es) * 2012-06-08 2018-02-23 Gilead Sciences, Inc. Inhibidores macrocíclicos de virus Flaviviridae
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8300536A (nl) 1983-02-14 1984-09-03 Oce Andeno Bv Optisch actief alfa-azido-p-hydroxyfenylazijnzuur en zijn zouten alsmede de bereiding daarvan.
JPS6124539A (ja) 1984-07-11 1986-02-03 Sagami Chem Res Center 光学活性(r)−2,5,12−トリヒドロキシ−1,2,3,4−テトラヒドロナフタセン−6,11−ジオン−2−カルボン酸の取得方法
JP4218040B2 (ja) 1997-12-26 2009-02-04 曽田香料株式会社 有機酸とアミンの複合塩の製造法
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 3,5,6−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
SI1713823T1 (sl) 2004-01-30 2010-04-30 Medivir Ab Inhibitorji HCV NS-3 serin proteaze
CN101146794A (zh) 2005-01-21 2008-03-19 阿斯泰克斯治疗有限公司 用于抑制cdk和gsk的吡唑衍生物
JP5171624B2 (ja) * 2005-07-29 2013-03-27 テイボテク・フアーマシユーチカルズ C型肝炎ウイルスの大環状阻害剤
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
HRP20100429T1 (hr) * 2007-02-01 2010-09-30 Tibotec Pharmaceuticals Postupci i intermedijeri za pripravu makrocikličkog inhibitora proteaze za hcv
JP5554570B2 (ja) * 2007-02-08 2014-07-23 ヤンセン・アールアンドデイ・アイルランド Hcv阻害大環状フェニルカルバメート
BRPI0923393B1 (pt) 2008-12-23 2018-06-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. "processos para preparar um inibidor de protease de hcv macrocíclico e intermediários e uso".

Also Published As

Publication number Publication date
SMT201300116B (it) 2013-11-08
JP2012513381A (ja) 2012-06-14
CN102264715A (zh) 2011-11-30
KR20110099048A (ko) 2011-09-05
EP2382198B1 (en) 2013-07-10
BRPI0923393A2 (pt) 2015-07-28
PL2382198T3 (pl) 2013-11-29
AR074863A1 (es) 2011-02-16
BRPI0923393B1 (pt) 2018-06-19
US20110257403A1 (en) 2011-10-20
US8927722B2 (en) 2015-01-06
US20150080577A1 (en) 2015-03-19
KR101734507B1 (ko) 2017-05-11
JP5687631B2 (ja) 2015-03-18
HRP20130906T1 (hr) 2013-10-25
CA2745565A1 (en) 2010-07-01
AU2009331530B2 (en) 2015-04-09
RU2011130895A (ru) 2013-01-27
CY1114488T1 (el) 2016-10-05
PT2382198E (pt) 2013-10-01
DK2382198T3 (da) 2013-09-30
IL213246A0 (en) 2011-07-31
WO2010072742A1 (en) 2010-07-01
US9115077B2 (en) 2015-08-25
CN102264715B (zh) 2015-12-02
TW201033205A (en) 2010-09-16
EP2382198A1 (en) 2011-11-02
IL213246A (en) 2017-10-31
HK1164839A1 (zh) 2012-09-28
SI2382198T1 (sl) 2013-11-29
MX2011006764A (es) 2011-08-03
AU2009331530A1 (en) 2011-06-23
TWI461424B (zh) 2014-11-21
RU2016120007A (ru) 2018-11-13
CA2745565C (en) 2017-03-07

Similar Documents

Publication Publication Date Title
ES2429013T3 (es) Procedimientos e intermedios para la preparación de un inhibidor macrocíclico de la proteasa de VHC
ES2345857T3 (es) Procesos y compuestos intermedios para la preparacion de un inhibidor macrociclico de la proteasa de vhc.
RU2628081C2 (ru) Способы и промежуточные соединения для получения макроциклических ингибиторов протеазы hcv
JP6235473B2 (ja) 大環状hcvプロテアーゼ阻害剤を製造するための方法および中間体
RU2588132C2 (ru) Способы и промежуточные соединения для получения макроциклического ингибитора протеазы вируса гепатита с
HK1164839B (en) Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
HK1137442B (en) Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv